Gensight Biologics SA

Gensight Biologics SA is a France-based company. The Company focuses on the development and commercialization of gene therapies for retinal neurodegenerative diseases and selected central nervous system disorders. It operates as a clinical-stage biopharmaceutical business specializing in innovative gene therapy platforms designed to preserve or restore vision in patients affected by severe ophthalmic conditions. Its activities are centered on two core technology platforms: Mitochondrial Targeting Sequence (MTS), which is used to address diseases linked to mitochondrial dysfunction, and optogenetics, which is intended to restore light sensitivity in retinal cells. It develops therapeutic candidates for inherited and acquired retinal disorders, including products designed for single-administration treatment through intravitreal injection. It conducts research, clinical development, and related commercialization activities in ophthalmology and neurodegenerative disease applications.